4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination - PubMed (original) (raw)
4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination
J T Tan et al. J Immunol. 2000.
Abstract
Peptide vaccination induces T cell activation and cytotoxic T cell development. In an effort to understand what factors can improve immune responses to peptide vaccination, the role of 4-1BB (CD137) costimulation was examined, since 4-1BB has been shown to promote T cell responses in other systems. 4-1BBL-deficient (-/-) and wild-type (+/+) mice were immunized with a lipidated lymphocytic choriomeningitis virus (LCMV) peptide NP396-404. Analysis of peptide-specific responses early after immunization by CTL assay, intracellular IFN-gamma staining, and IFN-gamma enzyme-linked immunospot assay (ELISPOT) indicated that CD8 T cell responses were reduced 3- to 10-fold in the absence of 4-1BB costimulation. Moreover, when agonistic anti-4-1BB Ab was given, CD8 T cell responses in 4-1BBL-/- mice were augmented to levels similar to those in 4-1BBL+/+ mice. Two months after immunization, 4-1BBL+/+ mice still had epitope-specific cells and were protected against viral challenge, demonstrating that peptide vaccination can induce long-term protection. In fact, 70% of CD8 T cells were specific for the immunizing peptide after viral challenge, demonstrating that strong, epitope-specific CD8 T cell responses are generated after peptide vaccination. In contrast, peptide-immunized 4-1BBL-/- mice had fewer epitope-specific cells and were impaired in their ability to resolve the infection. These results show that immunization with a single LCMV peptide provides long term protection against LCMV infection and point to costimulatory molecules such as 4-1BB as important components for generating protective immunity after vaccination.
Similar articles
- A switch in costimulation from CD28 to 4-1BB during primary versus secondary CD8 T cell response to influenza in vivo.
Bertram EM, Dawicki W, Sedgmen B, Bramson JL, Lynch DH, Watts TH. Bertram EM, et al. J Immunol. 2004 Jan 15;172(2):981-8. doi: 10.4049/jimmunol.172.2.981. J Immunol. 2004. PMID: 14707071 - 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
Cannons JL, Lau P, Ghumman B, DeBenedette MA, Yagita H, Okumura K, Watts TH. Cannons JL, et al. J Immunol. 2001 Aug 1;167(3):1313-24. doi: 10.4049/jimmunol.167.3.1313. J Immunol. 2001. PMID: 11466348 - Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.
Mittler RS, Foell J, McCausland M, Strahotin S, Niu L, Bapat A, Hewes LB. Mittler RS, et al. Immunol Res. 2004;29(1-3):197-208. doi: 10.1385/IR:29:1-3:197. Immunol Res. 2004. PMID: 15181282 Review. - Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy.
Sica G, Chen L. Sica G, et al. Arch Immunol Ther Exp (Warsz). 1999;47(5):275-9. Arch Immunol Ther Exp (Warsz). 1999. PMID: 10604232 Review.
Cited by
- 4-1BB immunotherapy: advances and hurdles.
Singh R, Kim YH, Lee SJ, Eom HS, Choi BK. Singh R, et al. Exp Mol Med. 2024 Feb;56(1):32-39. doi: 10.1038/s12276-023-01136-4. Epub 2024 Jan 4. Exp Mol Med. 2024. PMID: 38172595 Free PMC article. Review. - The 4-1BBζ costimulatory domain in chimeric antigen receptors enhances CD8+ T-cell functionality following T-cell receptor stimulation.
Chu GJ, Bailey CG, Nagarajah R, Sagnella SM, Adelstein S, Rasko JEJ. Chu GJ, et al. Cancer Cell Int. 2023 Dec 18;23(1):327. doi: 10.1186/s12935-023-03171-7. Cancer Cell Int. 2023. PMID: 38105188 Free PMC article. - Agonism of 4-1BB for immune therapy: a perspective on possibilities and complications.
Salek-Ardakani S, Zajonc DM, Croft M. Salek-Ardakani S, et al. Front Immunol. 2023 Aug 17;14:1228486. doi: 10.3389/fimmu.2023.1228486. eCollection 2023. Front Immunol. 2023. PMID: 37662949 Free PMC article. Review. - T cells protect against hepatitis A virus infection and limit infection-induced liver injury.
Misumi I, Mitchell JE, Lund MM, Cullen JM, Lemon SM, Whitmire JK. Misumi I, et al. J Hepatol. 2021 Dec;75(6):1323-1334. doi: 10.1016/j.jhep.2021.07.019. Epub 2021 Jul 29. J Hepatol. 2021. PMID: 34331968 Free PMC article. - The Murine CD137/CD137 Ligand Signalosome: A Signal Platform Generating Signal Complexity.
Choi BK, Lee HW. Choi BK, et al. Front Immunol. 2020 Dec 10;11:553715. doi: 10.3389/fimmu.2020.553715. eCollection 2020. Front Immunol. 2020. PMID: 33362756 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials